While anti-CD20 agents causes profound B cell exhaustion which increases infection risks, telitacicept modulates B cell maturation without eradicating the entire B cell pool, preserving regenerative capacity and selectively sparing APRIL-independent long-lived plasma cells to maintain protective immunity. The gene discussed is TNFSF13; the disease is infection.